NEXGEL, Inc. NXGLW
Nov 2, 2026, 3:57 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 922.77K
- Revenue (ttm)
- 5.01M
- Profit margin
- -67.60%
- EPS (ttm)
- -1.39
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 35
- Open
- 0.314
- Previous close
- 0.0118
- Day's range
- 0.0118 – 0.012
- 52-week range
- 0.0118 – 0.012
- Beta
- 0.73
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.40%
- Free cash flow
- -1.89M
- Total cash
- 1.07M
- Total debt
- 3.00M
- Return on equity
- -64.31%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About NEXGEL, Inc.
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- nexgel.com
News
NEXGEL Regains Compliance with Nasdaq Listing Requirement 
NEXGEL, Inc. (NASDAQ:NXGLW) Short Interest Update 
NEXGEL Announces Dial-In Details for Investor Update Call 
NEXGEL Announces Date for Investor Update Call 
NEXGEL Reports Second Quarter 2026 Financial Results 
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration 
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript 
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical 
NEXGEL To Report First Quarter 2026 Financial Results on May 15th 
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
Your note
Sign in to keep a note on NXGLW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 26.62% | 550,000 | 467.50K | Sep 29, 2024 |
| Altium Capital Management, LP | 10.89% | 225,000 | 191.25K | Sep 29, 2024 |
| Clear Street LLC | 2.47% | 51,114 | 43.45K | Sep 29, 2024 |